Relapsed, Refractory Myeloma Has Indirect Societal Costs
Patients with relapsed or refractory multiple myeloma experienced significant indirect social costs from their disease, in addition to the direct costs.
TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension.
Young Obese Men at Risk for Liver Cancer
Young men who are overweight or obese are at risk of developing severe liver disease or liver cancer in later life, particularly those who have type 2 diabetes mellitus.
Achieving Value in Cancer Care
This video explores the value proposition in cancer care, with practical considerations for reducing costs at both the hospital and physician level while maintaining optimal care for cancer patients.
FDA Approves Niraparib for Recurrent Ovarian Cancer
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Managing Thrombosis in Cancer Patients
This video reviews recommendations for the prevention and management of thrombosis in patients with cancer.
Novel Agent Active in Platinum-Resistant/Refractory Ovarian Cancer
A novel compound known as PM01183 showed promising activity in a two-stage phase II trial of women with platinum-resistant/refractory ovarian cancer.
Using Genetic Testing to Help Prevent Colon Cancer
In this interview we discuss the role of genetic testing in patients with colon cancer.
Several Actionable Targets Identified in Testicular Cancer
This video highlights recent research in cisplatin-resistant testicular cancer, including a study on whole exome sequencing that revealed several actionable targets.
Adjuvant TKI Use in High-Risk Clear Cell RCC Not Effective
Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.
By clicking Accept, you agree to become a member of the UBM Medica Community.